FindTrial
Sign In

Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of DW1903

A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics After Oral Administration of DW1903, DW1903-R1 and DW1903-R2 in Healthy Adult Volunteers

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05155072
Enrollment
31
Registered
2021-12-13
Start date
2020-05-15
Completion date
2020-09-07
Last updated
2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastritis

Brief summary

A Randomized, Open-label, Oral in healthy male volunteers

Interventions

DRUGDW1903

DW1903

DRUGDW1903-R1

DW1903-R1

DRUGDW1903-R2

DW1903-R2

Sponsors

Daewon Pharmaceutical Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
19 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Healthy Volunteers who are ≥19 years old * BMI between 18 and 30 kg/m2 * Body weight ≥50kg

Exclusion criteria

•Clinically significant Medical History

Design outcomes

Primary

MeasureTime frameDescription
pH monitoringup to day 5Pharmacodynamic Endpoint

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026